Letter to Dermatology
Benzimidazoles (albendazole, fenbendazole, oxfenbendazole,
mebendazole, thiabendazole) are broad antiparasitic agents used
Treatment of Scabies with Albendazole
against a wide range of nematodes and cestodes. By binding to free  -tubulin, benzimidazoles inhibit the polymerization of tu-
bulin and the microtubule-dependant glucose uptake, leading to
Université Saint-Joseph, Hôtel-Dieu de France, Beirut , Lebanon
parasitic death. These agents may additionally interfere with the synaptic transmission of parasites through a probable cholinergic effect [2] . Effectiveness of oral and topical thiabendazole against
scabies has been pointed out in few reports since the 1960s [3, 4],
and thiabendazole and the newer agent albendazole have been
successfully used against pediculosis capitis [2, 5] ; yet little atten-
Scabies is a highly communicable disease caused by infesta-
tion has been paid to the antiscabies properties of benzimidazoles,
tion with Sarcoptesscabiei var. hominis . Current treatments for
given the limited experience with these drugs in this setting. Our
scabies include benzyl benzoate, malathion, lindane and perme-
observations represent, to our knowledge, the first cases of scabies
thrin in addition to ivermectin [1] . The latter represents the only
successfully treated with oral albendazole and suggest that this
approved oral treatment for scabies and the therapeutic option for
agent provides a potential therapeutic option for scabies. Further
community-based treatment. Scabies outbreaks remain a serious
evaluation of the effectiveness of albendazole against scabies is
public health issue in Lebanon, and the failures of topical treat-
ment modalities prove challenging to manage, given the unavail-ability of ivermectin in our country. We report 2 patients with
scabies who were successfully treated with oral albendazole.
1 Chosidow O: Clinical practises. Scabies. N Engl J Med 2006; 354: 1718–
2 Namazi MR: Treatment of pediculosis capitis with thiabendazole: a
Case 1. A 63-year-old woman presented clinical evidence of
pilot study. Int J Dermatol 2003; 42: 973–976.
3 Hernandez-Perez E: Topically applied thiabendazole in the treatment
crusted scabies. Diagnosis was ascertained by skin scrapings pos-
of scabies. Arch Dermatol 1976; 112: 1400–1401.
itive for S. scabiei . Several head-to-toe applications of benzyl ben-
4 Allegre T, Cailleres S, Lota I, et al: Value of thiabendazole in scabies
zoate and lindane had been ineffective 2 months earlier. The pa-
resistant to local treatment in HIV infected patients. Presse Med 1992;
tient was prescribed a daily dose of 1,000 mg of albendazole with
fatty meals for 3 consecutive days and an application of a 5% sal-
5 Akisu C, Delibas SB, Aksoy U: Albendazole: single or combination
icylic acid ointment once daily for 1 week. The pruritus disap-
therapy with permethrin against pediculosis capitis. Pediatr Dermatol
peared within 5 days. Skin scrapings performed at the 1-week con-
trol visit on residual skin lesions did not reveal any Sarcoptes
mites. Lesions disappeared completely within 10 days. No side ef-
fects or recurrence were observed during 3 months of follow-up.
Université Saint-Joseph , Hôtel-Dieu de France
Case 2. A 76-year-old man with Alzheimer’s disease who had
PO Box 16 - 6830, Achrafieh, Beirut (Lebanon)
previously been treated with topical benzyl benzoate and per-
Tel. +961 3 664 604, Fax +961 1 616 160, E-Mail rtomb@usj.edu.lb
methrin had extensive scabies. Skin scraping revealed live Sarcop-tes . The patient was administered 3 daily doses of 1,000 mg of albendazole along with fatty meals. Skin lesions disappeared within 1 week. No recurrence was observed during the 2 months of follow-up.
Fax +41 61 306 12 34E-Mail karger@karger.ch
Prise en charge de la coprostase sévère Numéro 12 : Septembre 2008 ♦ prokinétiques (Primpéran®, Motilium®) ♦ utiliser des laxatifs à haute dose comme pour la préparation du tube digestif avant colonoscopie: Movicol® 8 sachets en l’espace de 6 heures, Fortran® 500ml, ou Cololyt® 500 ml d’une solution d’1 sachet /1 litre ♦ grand lavement pour stimuler le péristalti
L’ECHO VENDREDI 27 AVRIL 2012 David Brennan, directeur général d’AstraZeneca La crise? Pas pour tout le monde… d’Astra Zeneca jette l’éponge Après six ans à la tête du deuxième groupe pharmaceu- tique britannique, l’Américain doit céder sa place en raison de mauvais résultats financiers. «Superglue», JOHANN HARSCOËT, À LONDRES le chiffre d’aff